Overview
Jessica Stauring is an associate in the Litigation Department of Paul Hastings and is based in the firm’s New York office. Her practice focuses on complex, high-stakes litigation with an emphasis on intellectual property matters in the fields of pharmaceuticals and biotechnology, including patent infringement litigation in District Courts, post-grant validity challenges before the Patent Trial and Appeal Board, and appeals before the United States Court of Appeals for the Federal Circuit.
Jessica’s experience includes arguing before the Patent Trial and Appeal Board, first-chairing offensive expert witness depositions, arguing discovery disputes in federal court, drafting briefs and other submissions, and developing strategies related to infringement, validity, damages and IP ownership.
Jessica received her J.D., magna cum laude, from Drexel University Thomas R. Kline School of Law in 2021, where she served as the president of the Drexel Moot Court Board. During law school, Jessica interned for the Honorable Leonard P. Stark at the U.S. District Court for the District of Delaware. She earned a Bachelor of Science in Forensic and Toxicological Chemistry from West Chester University in 2013, whereafter she worked for private chemistry laboratories before attending law school. Jessica is admitted to practice law in New York.
Jessica currently serves as committee co-chair for the New York Intellectual Property Law Association.
Education
- Drexel University Thomas R. Kline School of Law, J.D. (magna cum laude), 2021
- West Chester University, B.S., 2013
Representations
- Merck Sharp & Dohme LLC v. The Johns Hopkins University
Represented Merck Sharp & Dohme LLC in nine inter partes review proceedings against The Johns Hopkins University before the U.S. Patent and Trademark Office Patent Trial and Appeal Board concerning patents directed to the use of PD-1 inhibitors, including Merck’s PD-1inhibitor (Keytruda®), in the treatment of certain types of cancer. Jessica co-led the oral hearing before the board and the board held all nine JHU patents unpatentable as anticipated and/or obvious. Jessica presently represents Merck in appeals of those decisions at the United States Court of Appeals for the Federal Circuit.
Jessica also presently represents Merck in the United States District Court for the District of Maryland in a breach of contract and declaratory judgment of non-infringement action brought by Merck against JHU involving the same patents subsequently held unpatentable by the board. The team successfully convinced the District Court to stay the proceedings following the Board’s institution of the first of nine inter partes review proceedings.
- Seagen Inc. v. Daiichi Sankyo Company Limited
Represented Daiichi Sankyo Company, Limited in a hotly contested complex arbitration and patent dispute worth billions of dollars concerning rights to biotechnology used for its antibody-drug conjugate (ADC) technology. Secured complete victory in a final award that dismissed the opposition’s claims as both substantively meritless and time-barred, and awarded the client $47 million in attorneys’ fees and costs.
- Daiichi Sankyo, Inc. v. Seagen Inc.
Secured complete victory for Daiichi Sankyo, Inc. at the United States Court of Appeals for the Federal Circuit in a consolidated appeal from a jury trial in the District Court for the Eastern District of Texas and a post-grant review proceeding at the U.S. Patent and Trademark Office Patent Trial and Appeal Board. Seagen’s antibody-drug conjugate patent was found invalid for failure to meet the written description and enablement requirements, and the jury’s finding of willful infringement and assessment of damages was vacated.
- Uptravi® and Uptravi® IV Litigations
Successfully litigated Hatch-Waxman challenges to compound, method of treatment, and crystal form patents on behalf of Actelion (a Johnson & Johnson company) and Nippon Shinyaku Co., Ltd in involving their innovative Uptravi® (selexipag) and Uptravi® IV (selexipag for injection) medications for the treatment of pulmonary arterial hypertension, achieving favorable settlements with generic challengers.
- Opsumit® Litigations
Secured favorable settlements on behalf of Actelion (a Johnson & Johnson company) with generic challengers in patent infringement actions involving its Opsumit® (macitentan) medication used to treat pulmonary arterial hypertension.
- Biogen Inc. et al. v. Neurimmune HOLDING AG et al.
Presently represents Biogen in declaratory judgment action in United States District Court for the District of Massachusetts to prevent against a wrongful attempt by Neurimmune to lay claim to Biogen’s independently-developed, proprietary, patent-pending technology, including a novel bispecific therapeutic.
Involvement
- Committee Co-Chair – New York Intellectual Property Law Association